tbuckley/cabot-search huggingface dataset:
Asymptomatic Hyperuricemia
Authors: AMY K. TAYLOR
Journal: Annals of Internal Medicine (1978)

Letters and Corrections1 September 1978Asymptomatic HyperuricemiaAMY K. TAYLOR, PH.D., SIMEON I. TAYLOR, M.D., PH.D.AMY K. TAYLOR, PH.D.Search for more papers by this author, SIMEON I. TAYLOR, M.D., PH.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-89-3-426_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: This letter is a comment on the economic analysis of the therapy of hyperuricemia as outlined by Liang and Fries (Ann Intern Med 88:666-670, 1978). They assume that the cost of therapy with allopurinol is $110 per year. From that they estimate a lifetime cost of $20 000 based on an interest rate of 7%. However, this calculation is misleading because it does not take time and the interest rate into account properly.A more useful approach is to calculate the present value (see Reference 1) of the total cost of a lifetime of allopurinol therapy. In...References1. PLISKINTAYLOR NA: General principles: cost-benefit and decision analysis, in Costs, Risks and Benefits of Surgery, edited by BUNKER JP, BARNES BA, MOSTELLER F. New York, Oxford University Press, 1977, pp. 5-27 Google Scholar2. SAMUELSON P: Economics. New York, McGraw-Hill Book Co., 1976, p. 509 Google Scholar1. YOUNGBOSWELLNIES JRA: Severe allopurinol hypersensitivity. Association with thiazides and prior renal compromise. Arch Intern Med 134:553-558, 1974 CrossrefMedlineGoogle Scholar2. WOODSEBELO'SULLIVAN MEW: Allopurinol and thiazides. Lancet 1:751, 1972 CrossrefMedlineGoogle Scholar3. UTSINGERYOUNG PW: Allopurinol hypersensitivity. Granular deposition of IgM at the dermal-epidermal junction. Am J Med 61:287-294, 1976 Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1978Volume 89, Issue 3Page: 426-427KeywordsAllopurinol Issue Published: 1 September 1978 PDF DownloadLoading ...
Miscellany
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE DOCTORATE OF PHILOSOPHY IN THE MEDICAL SCIENCES.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Listings
Journal: Annals of Internal Medicine (2001)

Book Listings3 July 2001Book ListingsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-1-200107030-00002 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Alternative MedicineAlternative and Complementary Treatment in Neurologic IllnessMI Weintraub, ed. 325 pages. Philadelphia: WB Saunders; 2001. $45.00. ISBN 0443065586. Order phone 215-238-7800.Clinician's Guide to Holistic MedicineRA Anderson. 421 pages. New York: McGraw-Hill; 2001. $35.00. ISBN 0071347143. Order phone 800-262-4729.Health Care and Spirituality: Listening, Assessing, CaringRB Gilbert, ed. 313 pages. Amityville, NY: Baywood; 2001. $37.00. ISBN 0895032503. Order phone 800-638-7819.Integrated Cancer Care: Holistic, Complementary, and Creative ApproachesJ Barraclough, ed. 292 pages. New York: Oxford Univ Pr; 2001. $45.00. ISBN 0192630954. Order phone 800-451-7556.CardiologyAtrial Flutter: From Mechanism to TreatmentAL Waldo. 64 pages. Armonk, NY: Futura; 2001. ... Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 3 July 2001Volume 135, Issue 1Page: B1KeywordsComputed axial tomography ePublished: 3 July 2001 Issue Published: 3 July 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Hepatic Encephalopathy
Authors: Cosmo L. Fraser, Allen I. Arieff
Journal: New England Journal of Medicine (1985)

Hepatic encephalopathy is a clinical syndrome characterized by abnormal mental status occurring in patients with severe hepatic insufficiency. It is a neuropsychiatric disorder associated with characteristic but nonspecific histologic lesions in the central nervous system.1 The clinical manifestations range from a slightly altered mental status to coma. The neuromuscular complications may range from incoordination and tremor to ophthalmoplegia and incontinence.The symptoms of hepatic coma are directly related to the rapidity with which hepatic failure develops and to its severity. The causes are numerous and have been reviewed elsewhere.2 With the advent of many new hepatotoxic drugs and the increased . . .
Deaths
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immunovirologic Control 24 Months After Interruption of Antiretroviral Therapy Initiated Close to HIV Seroconversion—Reply
Authors: Kholoud Porter, Sara Lodi, Laurence Meyer
Journal: JAMA Internal Medicine (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
The megasigmoid syndrome in psychotic patients
Authors: E. Kraft
Journal: JAMA (1966)

Sixteen cases of the megasigmoid syndrome were found. This uncommon disorder is predominantly observed in neuropsychiatric hospitals but not exclusively in psychotic patients. It is confined to the rectosigmoid. Significant features are paucity of symptoms despite severe constipation and bowel distention, relaxed anal sphincter with fecal incontinence, chronic proctosigmoiditis with fecal concrements and stercoraceous ulcers, and preservation of intramural ganglion cells. Roentgenographically, three different patterns can be distinguished. Presence of rectal gas with the patient in prone position rules out a sigmoid volvulus. Serious complications are perforation of stercoraceous ulcers, chronic toxemia, intestinal obstruction, and volvulus. The mortality can be lowered by early detection, especially from chest roentgenograms, and by appropriate therapy. A correlation appears to exist between the megasigmoid syndrome and lesions of the brain and the autonomic nervous system.
Correction to: CircLONP2 enhances colorectal carcinoma invasion and metastasis through modulating the maturation and exosomal dissemination of microRNA-17
Authors: Kai Han, Feng-Wei Wang, Chen-Hui Cao, Han Ling, Jie-Wei Chen, Ri-Xin Chen, Zi-Hao Feng, Jie Luo, Xiao-Han Jin, Jin-Ling Duan, Shu-Man Li, Ning-Fang Ma, Jing-Ping Yun, Xin-Yuan Guan, Zhi-Zhong Pan, Ping Lan, Rui-Hua Xu, Dan Xie
Journal: Molecular Cancer (2021)

An amendment to this paper has been published and can be accessed via the original article.
Abuse-Deterrent Opioid Formulations
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
More diabetics are being reviewed in general practice but without a proportionate decline in secondary care
Journal: BMJ (1998)

Some small for gestational age fetuses have higher risk of late fetal death than othersIn small for gestational age fetuses, without congenital malformations, constitutionally small fetuses-for example twins or the fetuses of short mothers-have been assumed to at lower risk of late fetal death than fetuses affected by conditions such as pre-eclampsia or cigarette consumption.Cnattingius et al (p 1483) tested that assumption in over 1 million births in the Swedish birth register.Overall, late fetal mortality was increased in women who were over 35, nulliparous, smoked, or were <155 cm tall and greatly increased in those with pre-eclampsia, essential hypertension, and twin pregnancies.But in very small for gestational age fetuses death rates were lower in women aged under 35, <155 cm tall, with twins, or with severe eclampsia or hypertension.
A simple method for selecting the dose of warfarin
Authors: J. Zatuchni
Journal: JAMA (1988)

<h3>To the Editor.</h3> —Regarding the article by Drs Hirsh and Levine entitled "The Optimal Intensity of Oral and Anticoagulant Therapy,"<sup>1</sup>I point out that the international normalized ratio system is not in wide use. There remains confusion about translation of results to estimating the dosage of warfarin. It is clear that anticoagulant control as prescribed by hospital physicians who apparently look at daily prothrombin times results in levels within the recommended range no more frequently than could be achieved by chance.<sup>2</sup> For these reasons, I wonder if Drs Hirsh and Levine would agree to a simple method for selection of warfarin dosage (Table). It is based on the prothrombin time reported by the laboratory in which a prothrombin time ratio of 1.3 to 1.5 corresponds to 14 to 15 s and that of 1.5 to 2.0 to 18 to 20 s, corresponding to an international normalized ratio of 2.0
Missing Conflict of Interest Disclosure
Journal: JAMA (2018)

Diana Mandelker, MD, PhD; Liying Zhang, MD, PhD; Yelena Kemel, MS, ScM; Zsofia K. Stadler, MD; Vijai Joseph, PhD; Ahmet Zehir, PhD; Nisha Pradhan, BA; Angela Arnold, MS; Michael F. Walsh, MD; Yirong Li, PhD; Anoop R. Balakrishnan, MS; Aijazuddin Syed, MS; Meera Prasad, MS; Khedoudja Nafa, PharmD, PhD; Maria I. Carlo, MD; Karen A. Cadoo, MD; Meg Sheehan, MS; Megan H. Fleischut, MS; Erin Salo-Mullen, MS, MPH; Magan Trottier, MS, MSc; Steven M. Lipkin, MD, PhD; Anne Lincoln, MS; Semanti Mukherjee, PhD; Vignesh Ravichandran, MS; Roy Cambria, BS; Jesse Galle, BA; Wassim Abida, MD, PhD; Marcia E. Arcila, MD; Ryma Benayed, PhD; Ronak Shah, MS; Kenneth Yu, MD; Dean F. Bajorin, MD; Jonathan A. Coleman, MD; Steven D. Leach, MD; Maeve A. Lowery, MD; Julio Garcia-Aguilar, MD, PhD; Philip W. Kantoff, MD; Charles L. Sawyers, MD; Maura N. Dickler, MD; Leonard Saltz, MD; Robert J. Motzer, MD; Eileen M. O’Reilly, MD; Howard I. Scher, MD; José Baselga, MD, PhD; David S. Klimstra, MD; David B. Solit, MD; David M. Hyman, MD; Michael F. Berger, PhD; Marc Ladanyi, MD; Mark E. Robson, MD; Kenneth Offit, MD, MPH
B.C.G. and Vole Bacillus Vaccines in the Prevention of Tuberculosis in Adolescence and Early Adult Life
Journal: BMJ (1963)

This paper reports the 15-year results of a controlled clinical trial of BCG and vole bacillus vaccines in the prevention of TB.Among 54 239 participants, 583 cases of TB developed, of which 70 % were ofpulmonary TB and 15 % of tuberculous pleural effusion without evidence of pulmonary TB.The annual incidence (per 1 000) of TB was 0.28 among the 13 598 BCG-vaccinated participants and 1.28 among the tuberculin-negative unvaccinated participants admitted concurrently (a 78 % reduction); for vole bacillus vaccine (5 817participants) thefigures were 0.29 and 1.50 (an 81 % reduction).Protection extended to all forms of TB (in particular, 10 cases of tuberculous meningitis or miliary pulmonary TB developed in unvaccinated, and none in vaccinated, participants) and was similar in the two sexes.It decreased gradually during the period but was still substantial * See page 383.
A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC).
Authors: Philippa Corrie, Wendi Qian, Bristi Basu, Juan W. Valle, Stephen Falk, Chinenyu Iwuji, Harpreet Singh Wasan, Daniel H. Palmer, Martin Scott-Brown, Jonathan Wadsley, Seema Safia Arif, John A. Bridgewater, David Propper, Roopinder Gillmore, Aarthi Gopinathan, Lisa Bax, Andrea Machin, Albrecht Neesse, David A. Tuveson, Duncan Ian Jodrell
Journal: Journal of Clinical Oncology (2017)

4100 Background: NabP+GEM chemotherapy improves survival compared with GEM monotherapy as treatment for mPDAC. A PDAC mouse model suggested that nabP potentiates GEM activity by reducing cytidine deaminase levels and scheduling may be critical to optimise clinical benefit. Methods: Patients (pts) were randomised to receive standard concomitant (CON) nabP+GEM or sequential (SEQ) administration, with nabP given 24 hours before GEM. After 6 cycles, pts benefiting from treatment could continue the same regimen until disease progression. The primary endpoint was progression-free survival (PFS) by RECIST v1.1; secondary endpoints included safety, objective response rate (ORR), overall survival (OS) and quality of life (QoL). Serial blood and baseline tumour samples were collected for exploratory biomarkers. Results: Between March 2014 and 2016, 146 pts (71 SEQ, 75 CON) were recruited. Median age (range) was 66 (45-82) years; Karnofsky performance status was 70 (in 12% pts), 80 (27%), 90 (38%) or 100 (24%); 47% had pancreatic head primaries; 84% had liver metastases. Median no. cycles received was 4 SEQ, 3 CON; 51 pts (35%) received ≥6 cycles of treatment (42% SEQ, 28% CON). A 24+2hr interval was achieved in &gt; 90% SEQ admin. Grade ≥3 adverse events experienced by ≥10% pts (SEQ, CON) were neutropaenia (54%, 30%; p = 0.003), febrile neutropaenia (12%, 12%), fatigue (22%, 15%), vomiting (7%, 11%) and anaemia (10%, 5%). G-CSF was administered at local investigator's discretion to 35 pts (23 SEQ, 12 CON; p = 0.015). To date, 112 pts have died. 6 month (m) PFS by SEQ and CON arms were 47% and 33%; median PFS were 5.8 and 4.0m; hazard ratio (HR) = 0.66, 95% CI = 0.46-0.95; 12m OS by SEQ and CON arms were 29% and 26%; median OS were 10.1 and 7.9m; HR = 0.88, 95% CI = 0.61-1.29. ORR was 50% SEQ and 33% CON (p = 0.065). Mean baseline QoL Global health status score was 60.6 SEQ and 63.4 CON. The mean change in QoL score from baseline at 24 weeks was -2.1 SEQ and -12.1 CON. Conclusions: Sequential delivery of nabP combined with GEM trended towards improving all clinically relevant efficacy end points: PFS, OS, and ORR. Translational correlates will be reported in due course. Clinical trial information: ISRCTN71070888.
Cyclosporine improves psoriasis in a double-blind study
Authors: C. N. Ellis
Journal: JAMA (1986)

In a double-blind trial, 21 patients with severe plaque psoriasis were randomly assigned to receive oral cyclosporine, 14 mg/kg/d, or its vehicle. After four weeks of therapy the 11 cyclosporine recipients had the following response to treatment: two had total clearing and six improved markedly, two moderately, and one minimally; whereas ten vehicle-treated patients showed no change or minimal improvement. Vehicle-treated patients, after a switch to cyclosporine for four weeks, demonstrated impressive improvement similar to that seen in patients who initially received only cyclosporine. Moderate or marked improvement or total clearing was noted in 17 (81%) of 21 and 20 (95%) of 21 after one and four weeks of therapy, respectively. Mitotic figures and leukotriene B4 levels in lesions decreased 86% and 64%, respectively, after seven days of cyclosporine therapy. Mononuclear (including activated T cells) and polymorphonuclear leukocyte infiltrates were markedly reduced in lesions of all patients after seven days of cyclosporine therapy. These results suggest that (1) psoriasis may have an immunologic basis mediated by activated T cells and/or other immune cells; (2) if a long-term regimen with a favorable efficacy—side effect ratio can be determined, cyclosporine would be a significant advance in the treatment of psoriasis. (<i>JAMA</i>1986;256:3110-3116)
Erratum: A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
Authors: Pierre Farmer, Hervé Bonnefoi, Pascale Anderle, David Cameron, Pratyaksha Wirapati, Véronique Becette, Sylvie André, Martine Piccart, Mario Campone, Etienne Brain, Gaëtan MacGrogan, Thierry Petit, Jacek Jassem, Frédéric Bibeau, Emmanuel Blot, Jan Bogaerts, Michel Aguet, Jonas Bergh, Richard Iggo, Mauro Delorenzi
Journal: Nature Medicine (2009)
Méta-analyse d'essais cliniques comparatifs randomisés contestant l'utilité de la préparation digestive avant exploration du grêle par capsule endoscopique.
Journal: Endoscopy (2018)

La présence de résidus alimentaires, de bulles et de bile peut gêner la bonne visualisation de la muqueuse et possiblement impacter la rentabilité diagnostique des examens par vidéocapsule endoscopique (VCE). Les fabricants de VCE ne recommandent qu’une diète liquide la veille et/ou être à jeun 12 heures avant l’examen. A ce jour, 6 meta-analyses ont évalué l’intérêt d’une préparation intestinale avant la réalisation de la capsule et les résultants sont discordants.
Paclitaxel Approved for Treatment of Certain Breast Cancer Patients
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal